university of washingtonmont treblant, quebec, canada (july) effects of pregnancy on cyp3a and...

7/3/2018

University of Washington School of Pharmacy

Curriculum Vitae

Mary F. Hebert, Pharm.D., FCCP Current Title and Department: Professor of Pharmacy Adjunct Professor of Obstetrics and Gynecology Academic Positions Held

1990 –94 Assistant Clinical Professor Division of Clinical Pharmacy School of Pharmacy University of California San Francisco, California 1993 – 94 Assistant Clinical Professor Department of Pharmacy School of Pharmacy University of California

San Francisco, California 1994 -96 Associate Clinical Professor Division of Clinical Pharmacy & Department of Pharmacy School of Pharmacy University of California San Francisco, California 1996-2005 Associate Professor Department of Pharmacy School of Pharmacy University of Washington Seattle, Washington

2005- Professor Department of Pharmacy School of Pharmacy Adjunct Professor Department of Obstetrics and Gynecology School of Medicine University of Washington Seattle, Washington

Professional Positions Held

Curriculum Vitae Mary F. Hebert

7/3/2018

1984 Intern Pharmacist Pay N Save Pharmacy San Francisco, California 1984-87 Intern Pharmacist Manhattan Pharmacy Seattle, Washington 1985 Intern Pharmacist Long's Drugs Pharmacy Hayward, California 1987 Extern Pharmacist Marin General Hospital Greenbrae, California 1987-88 Clinical Pharmacy Resident University of California San Francisco, California 1988-90 Immunology Therapeutics Fellow American College of Clinical Pharmacy University of California San Francisco, California 1990 –96 Clinical Pharmacist, Liver Transplant University of California San Francisco, California 1996-2007 Clinical Pharmacist, Liver Transplant University of Washington Medical Center Seattle, Washington 2007- Clinical Pharmacist, Obstetrics University of Washington Medical Center Seattle, Washington

Education


7/3/2018

1981-82 Pre-Pharmacy University of Washington Seattle, Washington 1982-83 Pre-Pharmacy California State University Hayward, California 1983-87 Pharm.D. University of California San Francisco, California 2017 The Pharmacist & Patient-Centered Diabetes Care A National Certificate Training Program APHA 2016-2018 University of Washington Leadership Excellence Program

Licensure

1987 Licentiate in Pharmacy California and Washington

Specialty/Subspecialty

Clinical Pharmacy – Transplantation, Liver Disease, Obstetric-fetal Pharmacology Honors and Awards

1987 Member, Rho Chi, Pharmacy Honor Fraternity 1987 Chief Clinical Pharmacy Resident 2002 Fellow, American College of Clinical Pharmacy 2018 University of Washington, Environmental Health and Safety, Laboratory Safety

Award 2018 Education Committee of the American College of Clinical Pharmacology selected

paper for quarterly ACCP Virtual Journal Club webinar series


7/3/2018

Memberships: Professional, Scientific and Scholarly Societies

American College of Clinical Pharmacy American Society of Transplantation American Association of Colleges of Pharmacy

TEACHING

University of Washington Courses Taught, Didactic Acad Course Number Nature of Hrs/Qtr Total Year Quarter and Title Contribution Instruction Enroll --------------------------------------------------------------------------------------------------------------------- 1996 Sp Pharmacy 585 Lecturer 2 15 Solid Organ Transplant 1996 F Pharmacy 485 Lecturer 2 70 Adv. Clin Pharm & Ther. III 1997 W Pharmacy 586 Facilitator 2 15 Lit. Eval. & Case Presentation 1997-2012 F, W, Sp Pharmacy 499 Course Coordinator 100 1-2 Indep. Study/Research 1998 Sp Pharmacy 511 Course Coordinator 20 10-15 Immunotherapeutics 1998 Sp Pharmaceutics 507 Lecturer 1 44 1998-1999 F,W,Sp Pharmacy 590 Co-Course Coordinator / 70 Thesis Preceptor 2 1998 Sp Pharmacy 562 Module Coord., Lecturer/ 12 70 Therapeutics Facilitator 40 8 1998 F Pharm 560 Facilitator 40 7 1999-2012 Sp Pharm 562 Lecturer 11 70 1999 Sp Pharm 533 Lecturer 1 20 1999 F Pharm 560 Lecturer 7 70 2000 Sp Pharm 562 Co-Course Coordinator 100 70 2001-2003 Sp Pharm 562 Facilitator 40 10-12 2004 Sp Pharm 562 Co-Course Coordinator 100 76


7/3/2018

2006-2011 Sp OBGYN 590/EPI 507 Lecturer 1 25 2008 W GEN ST 197B Lecturer 1 25 2010 F PHRMRA 524 Lecturer 1 57 2012 Sp BioEn 599 Lecturer 2 12 2012-2014 Sp Pharm 559 Lecturer 3 90 2012- Sp Pharbe 522 Lecturer 2 30 2012- Su, F, W, Sp Pharm 599 Course Coordinator 50 1 2012 F Pharm 564 Instructor 20 20 2013- W Pharm 561 Lecturer 3 100 2013- Sp Pharm 562 Lecturer 6 100 2013 W Pharm 565 Instructor 20 20 2013- Sp Pharm 301 Lecturer 1 100 2013- W Pharm 543 Facilitator 1 100 2014 W Pharm 593 Instructor 20 20 2014- Sp PharmP 522 Simulation Instructor 4 6 Foundations of Interprofessional Practice 2015- Sp Pharm 557 Lecturer 2 100 2015 F Pharm 564 Grader 4 100 2015- W Pharm 593 Instructor 4 40 2015- W Pharm 579 Lecturer 1 87 2015- W Pharm 565 Grader 4 87 2016- Sp Pharm 563 Grader 2 87 2016- F Pharm 558 Co-Coord/Lecturer 86 106 University of Washington Courses Taught, Clerkship Acad Course Number Nature of Hrs/Qtr Total Year Quarter and Title Contribution Instruction Enroll ---------------------------------------------------------------------------------------------------------------------


7/3/2018

1996-2007 F,W,Sp,S Pharmacy 575 & 576 Preceptor 60-80 0-1/month Solid Organ Transplant (Outpatient Liver Transplant Clinic) Outpatient liver transplant clinic is offered as a rotation to 1 student or 1 UWMC resident per month, 12 months per year. Clinic meets 1/2 day twice per week. 2011- F,W,Sp,S Pharmacy 576 Preceptor 60-80 0-1/month Obstetric-fetal Pharmacology UCSF Courses Taught Acad Course Number Nature of Hrs/Qtr Total Year Quarter and Title Contribution Instruction Enroll --------------------------------------------------------------------------------------------------------------------- 1989 –95 W Biochemistry 112B Lecturer 1 125 Clinical Correlation’s 1988-90 W Clinical Pharmacy 131 Conference Leader 40 12-15 1990-93 F Clinical Pharmacy 130 Lecturer 4 125 Liver Disease 1990 –96 F,W,Sp,S Clinical Pharmacy 148 Preceptor 80 4 Liver Transplant 1991 Sp Clinical Pharmacy 132 Lecturer 2 125 CMV F Clinical Pharmacy 130 Conference Leader 40 12-15 1991 –95 W Clinical Pharmacy 131 Lecturer 2 125 PUD/GERD '93, '95 W, Sp Clinical Pharmacy 170.02 Course Coordinator 20 48-70 Transplant Immunology Lecturer 1993 –95 Sp Clinical Pharmacy 120 Lecturer 6 125 Liver Disease 1992-96 F, W, Sp Clinical Pharmacy 135B Preceptor 10 1-2 Trainees Supervised Residents

1990 –96 UCSF Clinical Pharmacy Residents – While Assigned to Liver Transplant Service


7/3/2018

1997-2007 UW Pharmacy Residents - While Assigned to Liver Transplant Clinic

Fellows 1991-1993 Immunology Therapeutics Fellow Co-Preceptor (Denise Gomez) 1993 -1995 Immunology Therapeutics Fellows Co-Preceptor (Shirley Tsunoda, Tammy Chang) 1995-1997 Immunology Therapeutics Fellow Co-Preceptor (Leslie Floren) 1999-2001 Immunology Therapeutics Fellow Preceptor (Jeong M. Park - Jamie) 2005-2007 Immunology Therapeutics Fellow Preceptor (Yasar Tasnif) 2009-2010 Obstetric-fetal Pharmacology Postdoc Preceptor (Sara Eyal) 2011 Obstetric-fetal Pharmacology Fellow Preceptor (Lindsey Highstrom) 2012-2015 Obstetric-fetal Pharmacology Fellow Preceptor (Rachel Ryu) 2014-2015 Obstetric-fetal Pharmacology Postdoc Preceptor (Matthew Honaker) 2013-2015 Obstetric-fetal Pharmacology Postdoc Co-Preceptor (Laura Shireman) Trainees

2006-2007 T-32 Trainee Preceptor (Megan Buchanan)

2011 TL1 Multidisciplinary Predoctoral Clinical Research Training Program Preceptor (Tracy Yep) Programs Established

1992 –95 UCSF Transplant Teen Day (Organizational Committee Member, Medication Section Instructor)


7/3/2018

Graduate Students Supervisory Committee Member Marilee Andrew Xiaosu Ma Diana Shuster Nora Lee Songmao Zheng Elizabeth Dorfman Alexa Resler Michael Liao Lyrialle Han Graduate Student Regulatory Project Preceptor Alisha Bouge

PROFESSIONAL ACTIVITIES Consultantships

1992 –1993 Medco Research Inc. Pharmacokinetics Consultant 1994 Syntex Pharmaceuticals Clinical Research Consultant 1999 Wyeth-Ayerst Pharmaceuticals Consultant & Transplant Pharmacy Advisory Board Member 1999 Novartis Consultant & Pharmacy Advisory Board Member 2000 Fujisawa Pharmacy Advisory Board Member 2006 Nabi HB Pharmacy Advisory Board Member 2011 Expert Witness •Morgan Carlo Downs & Everton •Taylor Blessey LLP 2013 UBC Bioscience Consultant 2013 Hyperion Consultant 2015 Expert Witness

• Fain Anderson VanDerhoef Rosendahl O'Halloran Spillane, PLLC • Whipple Law Group


7/3/2018

2017 Expert Witness • PK LAW

Invited Lectures/Seminars National/International 1992 -96 Pharmacokinetics for Pharmaceutical Scientists. San Francisco, California 1995 Current Therapy for the Prevention and Treatment of Rejection American Nephrology Nurses Association 26th National Symposium Philadelphia, Pennsylvania (June) 1995 Advances in Immune Modulation American Nephrology Nurses Association 26th National Symposium Philadelphia, Pennsylvania (June) 2000 Post-Transplant Osteoporosis: A Cause of Significant Morbidity and Mortality American College of Clinical Pharmacy Annual Meeting Los Angeles, California (November)

2000 Significant Papers in Pharmacotherapy: Transplantation American College of Clinical Pharmacy Annual Meeting

Los Angeles, California (November)

2001 Strategies for Managing Drug Interactions in the Transplant Setting Current Best Practices in Transplantation, University of Michigan CE Program Marco Island, Florida (January)

2002 Drug Interactions in Transplantation

Building a Treatment Strategy for Long-term Transplant Patient Care, University of Michigan CE Program

Albuquerque, New Mexico (October)

2003 Pregnancy Studies – Can they be done? Drug Information Association, 39th Annual Meeting San Antonio TX (June)

2004 Clinical Challenges in Devising Drug Dosing Regimens for Pregnant Women AAPS Workshop, Pharmacokinetics and Pharmacodynamics of Drugs in Pregnant and Lactating Women: Issues and Challenges Arlington VA (May) Drug Interactions of Antifungal Agents: Implications for the Transplant Patient Management Strategies for Invasive Fungal Infections in Stem-Cell Transplant Patients, Imedex Inc. CE Program Cleveland Ohio (September)


7/3/2018

Drug Interactions of Antifungal Agents: Implications for the Transplant Patient Management Strategies for Invasive Fungal Infections in Stem-Cell Transplant Patients, Imedex Inc. CE Program San Francisco CA (November) Drug Interactions of Antifungal Agents: Implications for the Transplant Patient Management Strategies for Invasive Fungal Infections in Stem-Cell Transplant Patients, Imedex Inc. CE Program Pasadena CA (December)

2005 I titrated to response. Why do I need clinical pharmacology Diabetes in Pregnancy Study Group of North America Washington DC (April) Maternal-Fetal Pharmacology – Present Issues, Future Perspectives Keynote Speaker, 2nd Canadian Therapeutics Congress Joint Scientific Meeting Vancouver, British Columbia (April)

Pharmacologic considerations in the treatment of fungal infections in solid organ transplant recipients

Fungal Infections in Solid Organ Transplant Patients Seattle, WA (May)

Pharmacologic considerations in the treatment of fungal infections in solid organ transplant recipients

Fungal Infections in Solid Organ Transplant Patients Indianapolis, IN (June) Impact of Pregnancy on Pharmacokinetics – Part 1 Summer Institute in Maternal-Fetal Pharmacology Mont Treblant, Quebec, Canada (July) Impact of Pregnancy on Pharmacokinetics – Part 2 Summer Institute in Maternal-Fetal Pharmacology Mont Treblant, Quebec, Canada (July) Clinical Pharmacokinetic Cases Summer Institute in Maternal-Fetal Pharmacology Mont Treblant, Quebec, Canada (July) Effects of Pregnancy on CYP3A and P-glycoprotein Activity ORWH Specialized Centers of Research (SCOR) Directors Meeting Bethesda MD (October) Drug Interactions with Antifungal Therapy in Solid Organ Transplant Recipients

Invasive Fungal Infections: Treatment Advances, Clinical Challenges Seattle, WA (November) Drug Interactions with Antifungal Therapy in Solid Organ Transplant Recipients

Invasive Fungal Infections: Treatment Advances, Clinical Challenges Seattle, WA (December)


7/3/2018

2006 Drug Interactions with Antifungal Therapy in Solid Organ Transplant Recipients Invasive Fungal Infections: Treatment Advances, Clinical Challenges

Seattle, WA (January) Drug Interactions with Antifungal Therapy in Solid Organ Transplant Recipients

Invasive Fungal Infections: Treatment Advances, Clinical Challenges Seattle, WA (February)

Therapeutic and Research Challenges in Pregnancy – Where Do We Go from Here?

Society for Gynecologic Investigation Annual Meeting Toronto ON, Canada (March) Pregnancy Affects the In Vivo Activities of Cytochrome P450 3A (CYP3A) and P-

glycoprotein Third Annual Interdisciplinary Women’s Health Research Symposium Bethesda, MD (November) 2007 Impact of Pregnancy Changes on Pharmacokinetics Part I 3rd Annual Summer Institutes, Maternal-Fetal Pharmacology, Reproductive and

Perinatal Epidemiology Bromont, Quebec Canada (July) Impact of Pregnancy Changes on Pharmacokinetics Part II 3rd Annual Summer Institutes, Maternal-Fetal Pharmacology, Reproductive and

Perinatal Epidemiology Bromont, Quebec Canada (July) Hands on Pharmacokinetics in Pregnancy and Lactation 3rd Annual Summer Institutes, Maternal-Fetal Pharmacology, Reproductive and

Perinatal Epidemiology Bromont, Quebec Canada (July) Building a Career in OB Pharmacology 3rd Annual Summer Institutes, Maternal-Fetal Pharmacology, Reproductive and

Perinatal Epidemiology Bromont, Quebec Canada (July)

Clinical Pharmacology of Medications in Pregnancy: Benchtop to Bedside American College of Clinical Pharmacy Annual Meeting Denver, CO (October) Drug Interactions Involving Metabolic Enzymes: A Case Study Part I American College of Clinical Pharmacy Annual Meeting Denver, CO (October) Drug Interactions Involving Metabolic Enzymes: A Case Study Part II American College of Clinical Pharmacy Annual Meeting Denver, CO (October) 2008 The OPRU Approach to Gestational Diabetes NICHD Council Meeting


7/3/2018

Bethesda MD (January) Clinical Pharmacology of Drugs in Pregnancy and Lactation: Moving Beyond

Guessing University of Michigan Seminar Series Ann Arbor MI (February) Clinical Relevance of Pharmacokinetics in Pregnancy FDA/CDER Spring 2008 Maternal Health Team Course Silver Spring MD (April)

Pharmacokinetics and Pharmacodynamics of Glyburide of Gestational Diabetes FDA Clinical Pharmacology Group Silver Spring MD (April) Clinical Relevance of Pharmacokinetic Changes during Pregnancy University of Texas Medical Branch Obstetrics and Gynecology Grand Rounds Galveston TX (May) Glyburide for Gestational Diabetes University of Texas Medical Branch Obstetrics and Gynecology Research Forum Galveston TX (May)

Impact of Pregnancy Changes on Pharmacokinetics Part I 4th Annual Summer Institutes, Maternal-Fetal Pharmacology Burlington, Vermont (July) Impact of Pregnancy Changes on Pharmacokinetics Part II 4th Annual Summer Institutes, Maternal-Fetal Pharmacology Burlington, Vermont (July) Hands on Pharmacokinetics in Pregnancy and Lactation 4th Annual Summer Institutes, Maternal-Fetal Pharmacology Burlington, Vermont (July) The Clinical Relevance of Pharmacokinetic Changes during Pregnancy IXth World Conference on Clinical Pharmacology and Therapeutics Quebec City, Canada (July) Pharmacokinetics and Disposition of Drugs Commonly Administered during

Pregnancy 15th Annual ISSX North American Regional Meeting San Diego CA (October) 2009 Clinical Pharmacology in Pregnancy: PK/PD ASCPT Annual Meeting National Harbor, Maryland (March) Pharmacogenomics BCPA Pharmacogenomics Workshop Rockville MD (April)


7/3/2018

Gestational Diabetes, Can Pharmacokinetics and Pharmacodynamics Help Optimize Care?

2009 Diabetes in Pregnancy Study Group - West Meeting Seattle WA (May) 2nd International Conference on Individualized Pharmacotherapy in Pregnancy Indianapolis IN (May) Pharmacodynamics & Pharmacokinetics of Glyburide in Pregnancy European Society for Developmental Perinatal & Paediatric Pharmacology Chamonix France (June)

Impact of Pregnancy Changes on Pharmacokinetics Part I 5th Annual Summer Institutes, Maternal-Fetal Pharmacology Montreal, Quebec (July) Impact of Pregnancy Changes on Pharmacokinetics Part II 5th Annual Summer Institutes, Maternal-Fetal Pharmacology Montreal, Quebec (July) Hands on Pharmacokinetics in Pregnancy and Lactation 5th Annual Summer Institutes, Maternal-Fetal Pharmacology Montreal, Quebec (July)

Building a Career in Obstetric-Fetal Pharmacology 5th Annual Summer Institutes, Maternal-Fetal Pharmacology Montreal, Quebec (July)

Perinatal Pharmacology 50th Annual Meeting of the European Society for Paediatric Research Hamburg, Germany (October) 2010 How Sweet It Is – Taking a Second Look at Hypoglycemic Agents in Pregnancy 3rd International Conference for Individualized Pharmacotherapy in Pregnancy Indianapolis IN (June) Hurdles to Recruitment and Studying Pregnant Women 3rd International Conference for Individualized Pharmacotherapy in Pregnancy Indianapolis IN (June)

Glyburide and Metformin – Drug Therapy during Pregnancy—Safety and Effectiveness American Diabetes Association 70th Scientific Session Orlando FL (June)

Impact of Pregnancy Changes on Pharmacokinetics Part I 6th Annual Summer Institutes, Maternal-Fetal Pharmacology St. Michaels MD (July) Impact of Pregnancy Changes on Pharmacokinetics Part II 6th Annual Summer Institutes, Maternal-Fetal Pharmacology St. Michaels MD (July)


7/3/2018

Hands on Pharmacokinetics in Pregnancy and Lactation 6th Annual Summer Institutes, Maternal-Fetal Pharmacology St. Michaels MD (July)

Building a Career in Obstetric-Fetal Pharmacology 6th Annual Summer Institutes, Maternal-Fetal Pharmacology St. Michaels MD (July) Clinical Pharmacology of Drugs Used to Manage Gestational Diabetes Food and Drug Administration, Clinical Pharmacology Seminar Bethesda MD (November) 2011 Pharmacometrics in Pregnancy: the Unmet Need American Conference on Pharmacometrics Coronado CA (April) PK and PD of Atenolol in Pregnancy FDA Office of Women’s Health Pregnancy and Prescription Medication Use Symposium White Oak MD (May) PK of Amoxicillin during Pregnancy and Postpartum FDA Office of Women’s Health Pregnancy and Prescription Medication Use Symposium White Oak MD (May) Drugs in Pregnancy: How You Counsel Patients Matters NW Pharmacy Convention Coeur d’Alene ID (June)

Impact of Pregnancy Changes on Pharmacokinetics Part I 7th Annual Summer Institutes, Maternal-Fetal Pharmacology Montreal, Quebec (July) Impact of Pregnancy Changes on Pharmacokinetics Part II 7th Annual Summer Institutes, Maternal-Fetal Pharmacology Montreal, Quebec (July) Hands on Pharmacokinetics in Pregnancy and Lactation 7th Annual Summer Institutes, Maternal-Fetal Pharmacology Montreal, Quebec (July)

Clinical Pharmacology of Glyburide and Metformin in Pregnancy 7th Annual Summer Institutes, Maternal-Fetal Pharmacology Montreal, Quebec (July) 2012 Overview of the effects of pregnancy on drug disposition

FDA Workshop: Development of animal models of pregnancy to address medical countermeasures in the “at risk” population of pregnant women: influenza as a case study

Silver Spring MD (April)


7/3/2018

Impact of Pregnancy Changes on Pharmacokinetics Part I 8th Annual Summer Institutes, Maternal-Fetal Pharmacology Toronto, Canada (July) Impact of Pregnancy Changes on Pharmacokinetics Part II 8th Annual Summer Institutes, Maternal-Fetal Pharmacology Toronto, Canada (July) Hands on Pharmacokinetics in Pregnancy and Lactation 8th Annual Summer Institutes, Maternal-Fetal Pharmacology Toronto, Canada (July)

Clinical Pharmacology of Glyburide and Metformin in Pregnancy 8th Annual Summer Institutes, Maternal-Fetal Pharmacology Toronto, Canada (July) 2013 Treating the mother, protecting the unborn Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Clinical Pharmacology International Webinar (March) Pharmacokinetic Changes in Pregnancy American Society of Pharmacology and Experimental Therapeutics and Canadian Society of Pharmacology and Therapeutics Boston, MA (April)

Impact of Pregnancy Changes on Pharmacokinetics Part I 9th Annual Summer Institutes, Maternal-Fetal Pharmacology Toronto, Canada (July) Impact of Pregnancy Changes on Pharmacokinetics Part II 9th Annual Summer Institutes, Maternal-Fetal Pharmacology Toronto, Canada (July) Hands on Pharmacokinetics in Pregnancy and Lactation 9th Annual Summer Institutes, Maternal-Fetal Pharmacology Toronto, Canada (July)

Clinical Pharmacology of Glyburide and Metformin in Pregnancy 9th Annual Summer Institutes, Maternal-Fetal Pharmacology Toronto, Canada (July) Career Planning in Obstetric-fetal Pharmacology 9th Annual Summer Institutes, Maternal-Fetal Pharmacology Toronto, Canada (July) 2014 Drugs in Pregnancy: Treating the Mother, Protecting the Unborn 2013-14 NICHD’s Principles of Pediatric Clinical Pharmacology Webinar (April) What’s New in Drug Therapy for Pregnancy? A Clinical Pharmacology Update


7/3/2018

Advanced Practice in Primary and Acute Care Conference Seattle WA (October) 2016 Lactation Study Basics, Lessons Learned. FDA’s Division of Pediatric and Maternal Health Lactation Public Workshop Silver Springs MD (April) 2017 Why some drugs don’t seem to work and other cause more frequent side effects during pregnancy – A look at changes in drug exposure during pregnancy Society for Obstetric Anesthesia and Perinatology Bellevue WA (May) 2018 Clinical implications of pharmacokinetic changes during pregnancy Society for Toxicology Annual Meeting San Antonio TX (March) Prednisone pharmacokinetics during pregnancy and lactation American College of Clinical Pharmacology Virtual Journal Club Webinar Seattle WA (September) State

1990 Post Liver Transplant Therapy: Use of Immunomodulators, CSHP Seminar '90. Santa Clara, California (October) 1993 Liver Transplant, CSHP Seminar '93 San Francisco, California (October) 1996 Immunosuppressant Drug Interactions. Current Clinical Drug Interactions University of Washington Continuing Pharmacy Education Conference Seattle, Washington (October)

2005 Drugs and Pregnancy: A Renal Transplant Perspective 100th Nephrology Days Seattle, Washington (October) Medication Use During Pregnancy and Lactation Women’s Health Update Seattle, Washington (November) 2006 Bringing the Benchtop to the Bedside Drugs in Pregnancy: Benchtop to Bedside Seattle, Washington (April)

Oral Hypoglycemic Agents: Clinical Implications of PK/PD Changes in Pregnancy

Drugs in Pregnancy: Benchtop to Bedside Seattle, Washington (April)


7/3/2018

2011 Clinical Implications of Pharmacokinetic Changes in Pregnancy Washington State OB Association Seattle, Washington (December)

2012 Clinical Pharmacology of Drugs in Pregnancy OBGYN Grand Rounds

Joint Base Lewis McChord, Washington (August) Drugs in Breast Milk

Washington OB Association Annual Meeting Seattle, Washington (November) 2014 Drugs in Pregnancy and Lactation Women’s Health Care Update Seattle, Washington (March) What is new in Drug Therapy in Pregnancy? A Clinical Pharmacology Update Advanced Practice in Primary and Acute Care conference Seattle, Washington (October)

Local

1990 Immunosuppression. Transplant Nursing Education and Training Program. San

Francisco, California (September) 1991 New Drugs in Transplantation. Transplant Nursing Education Program. San

Francisco, California (September) 1992 Immunosuppressive Therapy in Organ Transplant Patients. UCSF Staff

Development Program. San Francisco, California (April) 1992 New Drugs in Organ Transplant. Transplant Special Interest Group. San

Francisco, California (February) 1993 Liver Transplantation. UCSF Staff Development Program. San Francisco,

California (April) 1993 Immunosuppressives in Transplantation. Mount Zion Medical Grand Rounds. San

Francisco, California (March) 1994 Update on New Drugs in Liver Transplant. UCSF Pediatric G.I. Grand Rounds. San Francisco, California (April) 1996 Mycophenolate Mofetil. U of W Transplant Grand Rounds, Seattle, Washington (April) 1996 The Effects of Ketoconazole on the Pharmacokinetic Disposition of Tacrolimus. Department of Pharmacy Seminar Series. Seattle Washington (May)


7/3/2018

1998 Immunosuppressive Drug Interactions. UW Transplant Grand Rounds, Seattle, Washington (April) 2000 Osteoporosis in Transplantation: A Causes of Significant Morbidity and Mortality. UW Transplant Grand Rounds, Seattle, Washington (October)

2002 CYP3A5 / MDR1 genotype and post-liver transplantation renal dysfunction. UW Transplant Grand Rounds, Seattle, Washington (November)

2003 Research Update. UW, Clinical Research Unit, Seattle, Washington (June)

2005 Medications in Pregnancy: What’s New? UW Pharmacy Grand Rounds, Seattle,

Washington (April)

Drugs in Pregnancy UW, General Clinical Research Unit Scientific Advisory Committee Seattle, Washington (November) 2006 Medications in Pregnancy: OPRU Update UW OBGYN Grand Rounds Seattle, Washington (April) GI Drugs in Pregnancy UW GI Grand Rounds Seattle, Washington (April) 2007 Medications in Pregnancy UW Pharmacy Residents Seattle, Washington (January) Drug Interactions in Solid Organ Transplantation Transplantation Residents Conference Seattle, Washington (May) 2008 Gestational Diabetes UWMC Maternal Infant Care Diabetes Conference Seattle, Washington (January)

Pregnancy, Prescriptions and Pharmacodynamics: Researching the Risks. The Pharmacology Perspective UW Uncorking Ethics Series Seattle, Washington (October)

2010 Drugs in Pregnancy: How you Counsel Patients Matters UWMC Pharmacy Conference Seattle, Washington (September) Drugs in Pregnancy: How you Counsel Patients Matters Harborview Medical Center Seattle, Washington (November)


7/3/2018

2011 How Sweet It Is – Taking a Second Look at the Clinical Pharmacology of Oral Hypoglycemic Agents in Gestational Diabetes Mellitus UW Obstetrics and Gynecology Grand Rounds Seattle, Washington (March)

2012 Clinical Implications of Pharmacokinetic Changes during Pregnancy

Pharmacy for Reproductive Education and Sexual Health, Pharmacy Students Conference Seattle, Washington (January)

Medications in Pregnancy and Lactation

Annual Perinatal Conference Kirkland, Washington (May) Drugs in Pregnancy and Lactation UWMC Neonatal Fellows Conference Seattle, Washington (May) 2013 Interpreting Tacrolimus Concentrations during Pregnancy Transplantation Grand Rounds Seattle, Washington (February) 2016 OTC Medications during Pregnancy UWMC Nurses Conference Seattle, Washington (April)

Papers and Posters Presented at Meetings

1989 Hebert MF, Garovoy M, Amend W, Gambertoglio JG. The effects of histamine

type-2 receptor antagonists on the immune system. American College of Clinical Pharmacy Annual Meeting. Kansas City, Missouri (August)

Hebert MF, Pons VG, Flaherty JF. Cefotaxime pharmacodynamics in acute

nosocomial pneumonia. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, Texas (October)

1990 Flaherty JF, Hebert MF, Pons VG, Jacobs RA. Acute nosocomial pneumonia does

not influence cefotaxime disposition. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia (October)

1991 Hebert MF, Roberts JP, Gambertoglio JG, Benet LZ. The effects of rifampin on

cyclosporine pharmacokinetics. American Society of Clinical Pharmacology and Therapeutics. San Antonio, Texas (March)


7/3/2018

Hebert MF, Ascher NL, Lake JR, Roberts JP. Efficacy and toxicity of FK506 for the treatment of resistant rejection in liver transplant patients. First International Symposium on FK 506. Pittsburgh, Pennsylvania (August)

Freise CE, Rowley H, Lake J. Hebert MF, Ascher NL, Roberts JP. Similar clinical

presentation of neurotoxicity following FK506 and CSA in liver transplant recipient. First International Symposium on FK506. Pittsburgh, Pennsylvania (August)

d'Uscio CH, Hebert MF, Prueksaritanont T, Gumbert MV, Gupta SK, Gambertoglio

JG, Garovoy MR, Benet LZ. The effects of rifampin on cyclosporine immunopharmacodynamics in healthy volunteers. American Association of Pharmaceutical Scientists. Washington, DC (November)

1992 Roberts JP, Hebert M, Nikolai B, Lake J, Kauffman RS, Ascher N. Maintenance

therapy with prednisone and RS61443 alone following liver transplantation. International Liver Transplantation Symposium. Minneapolis, Minnesota (May)

Hebert MF, Ascher NL, Benet LZ, Shah J, Roberts JP. Pharmacokinetics of oral 2-

(4-morpholino) ethyl ester of mycophenolic acid (EE-MA) in liver transplant patients. American Society of Clinical Pharmacology and Therapeutics. Orlando, Florida (March)

1993 Lee C, Jusco W, Shaefer M, Klintmalm G, Hebert M, Piergies A, Schechter P, Mekki

Q. Pharmacokinetics of Tacrolimus (FK506) in Liver Transplant Patients. American Society of Clinical Pharmacology and Therapeutics. Honolulu, Hawaii (March)

Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Clinical Evidence of

Metabolic Differences Between Intestinal and Hepatic Cytochrome P450. American Society of Clinical Pharmacology and Therapeutics. Honolulu, Hawaii (March)

Iannuci A, Hebert MF. A Review of the Impact of Pre-Transplant Infection and

Antibiotic Use on Post-Transplant Clinical Course in Liver Transplant Patients. Western States Conference. Monterey, California (April)

1994 Hebert MF, Benet LZ, Gomez D, Lee R, Linna TJ, Shah J, Roberts JP.

Pharmacokinetics (PK) of Oral Mycophenolate Mofetil (MM) in Liver Transplant Patients. American Society of Clinical Pharmacology and Therapeutics. New Orleans, Louisiana (March)

Gomez D, Hebert M, Benet LZ. The Effect of Ketoconazole on the Intestinal

Metabolism and Bioavailability of Cyclosporine. American Society of Clinical Pharmacology and Therapeutics. New Orleans, Louisiana (March).

Hebert M, Ascher N, Lake J, Emond J, Linna TJ, Shah J, Nikolai B, Roberts J.

Mycophenolate Mofetil for Prophylaxis Against Rejection Following Orthotopic Liver Transplantation. XVth World Congress of the Transplantation Society. Kyoto, Japan (August).


7/3/2018

1995 Hebert MF, Wacher VJ, Benet LZ. Cyclosporine Pharmacokinetics Pre- and Post-Liver Transplantation. American Society of Clinical Pharmacology and Therapeutics. San Diego, California (March).

Chang T, Benet LZ, Hebert MF. The Effect of Water-soluble Vitamin E (TPGS) on

Oral Cyclosporine Pharmacokinetics in Healthy Volunteers. American Society of Clinical Pharmacology and Therapeutics. San Diego, California (March).

Tsunoda SM, Harris RZ, Mroczkowski PJ, Hebert MF, Benet LZ. Oral

Progesterone Therapy does not affect the Pharmacokinetics of Prednisolone and Erythromycin in Post-Menopausal Women. American Society of Clinical Pharmacology and Therapeutics. San Diego, California (March).

1996 Hebert MF, Chang T, Linna TJ, Hale MD, Roberts JP. Pharmacokinetics (PK) of

Intravenous Mycophenolate Mofetil (MMF) in Liver Transplant Patients. American Society of Clinical Pharmacology and Therapeutics. Orlando, Florida (March).

Floren LC, Bekersky I, Benet LZ, Mekki QA, Dressler DE, Lee JW, Roberts JP,

Hebert MF. The Effects of Ketoconazole on the Pharmacokinetic Disposition of Tacrolimus. Eighth Japanese-American Conference on Pharmacokinetics and Biophamaceutics. Seattle, Washington (July).

Floren LC, Bekersky I, Benet LZ, Mekki QA, Dressler DE, Lee JW, Roberts JP,

Hebert MF. The Effects of Ketoconazole on the Pharmacokinetic Disposition of Tacrolimus. American Association of Pharmaceutical Scientists Annual Meeting. Seattle, Washington (October).

1998 Hebert MF, Hebert JF, Gardner J, Hebert KR. Patient Satisfaction and Safety of a

Community-Pharmacy-Based Vaccination Program. American College of Clinical Pharmacy Annual Meeting. Cincinnati OH (November).

Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of Rifampin on

Tacrolimus Pharmacokinetics in Healthy Volunteers. American College of Clinical Pharmacy Annual Meeting. Cincinnati OH (November).

1999 The Mycophenolate Liver Transplant Study Group. A randomized, double-blind

comparative study of mycophenolate mofetil (MMF) and azathioprine (AZA), in combination with cyclosporine and corticosteroids in liver transplant recipients. American Association for the Study of Liver Diseases, Dallas TX (November)

2000 The Mycophenolate Liver Transplant Study Group. Efficacy of mycophenolate

mofetil in liver transplant recipients: results of a randomized double blind comparative study with an analysis of the impact of hepatitis C. American Society of Transplantation & American Society of Transplant Surgeons Joint Meeting, Chicago IL (May)

The Mycophenolate Liver Transplant Study Group. Efficacy and safety of

mycophenolate mofetil (MMF) after liver transplantation (OLT): results of a double-blind randomized trial. International Transplantation Congress, Rome Italy (August)


7/3/2018

The Mycophenolate Liver Transplant Study Group. Safety, Efficacy and Pharmacokinetics of mycophenolate mofetil in liver transplantation: results of a multicenter, randomized, double blind trial. Sixth International Liver Transplantation Society Congress, Buenos Aires Argentina (June)

Park J, Carithers RL, Larson A, Glue P, Hebert MF. Single-dose and multiple-dose

pharmacokinetics of interferon alpha-2b in chronic hepatitis C patients. American College of Clinical Pharmacy Annual Meeting, Los Angeles CA (November)

2002 Park JM, Calamia JC, Thummel KE, Slattery JS, Carithers RL, Marsh CL, Hebert

MF. CYP2E1 activity post-orthotopic liver transplantation (OLT). American Society of Clinical Pharmacology and Therapeutics, Atlanta Georgia (March)

Gierwatowski CB, Thummel KE, Davis CL, Dowling A, Hebert MF. Factors

associated with calcineurin-Inhibitor induced renal insufficiency. American College of Clinical Pharmacy Annual Meeting, Albuquerque NM (October)

2003 Dowling ALS, Gierwatowski C, Edwards KL, Lin YS, Davis CL, Marsh CL, Schuetz

EG, Hebert MF, Thummel KE. Association between CYP3A5 or MDR1 genotype and post-liver transplantation renal dysfunction among patients receiving calcineurin inhibitors. Pharmacogenetics Research Network and Knowledge Base 3rd Scientific Meeting, Memphis TN (March)

Hebert MF, Park JM, Chen Y-L, Akhtar S, Larson AM. Effects of St. John’s wort on

tacrolimus pharmacokinetics in healthy volunteers. American College of Clinical Pharmacy Spring Forum, Palm Springs CA (April)

Thummel K, Hebert M, Davis C. Metabolism and transport of calcineurin

inhibitors in human kidney: implications for drug-induced nephrotoxicity. ISSX, Sunny Providence RI (October).

2004 Bennett RJ, Easterling TR, Shen D, Carr DB, Hebert MF. Pharmacokinetics of

amoxicillin during pregnancy and postpartum. American College of Clinical Pharmacy Annual Meeting, Dallas TX (October)

Dai Y, Hebert MF, Thummel KE. Comparison of the in vitro intrinsic clearance of

tacrolimus by CYP3A4 and CYP3A5 using a substrate disappearance approach. Pharmaceutical Sciences World Congress, Kyoto, Japan (June)

2005 Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Mao Q.

Immunosuppressants are potent inhibitors of human breast cancer resistance protein (BCRP). AAPS Workshop, Nashville TN (November)

2006 Hebert MF, Unadkat JD, Carr DB, Kirby B, Thummel K, Eckert LO, Easterling TR.

The effects of pregnancy on cytochrome P450 (CYP3A) and P-glycoprotein (P-gp) activity. Society of Gynecologic Investigation Annual Meeting, Toronto Canada (March)

Naraharisetti SB, Hebert MF, Unadkat JD. Cytochrome P450 isoforms involved in

the metabolism of glyburide: an OPRU study. 14th North American ISSX Meeting, Rio Grande, Puerto Rico (October)


7/3/2018

Smith HE, Kalhorn T, Jones JP, Farin FM, Janssen P, Hebert MF, Thummel KE, Totah R. Role of CYP2C8 and CYP2J2 genotype in renal induced toxicity of calcineurin inhibitors. 14th North American ISSX Meeting, Rio Grande, Puerto Rico (October)

Dickmann LJ, Senn T, Tay S, Unadkat JD, Isoherranen N, Hebert MF. Changes in

CYP2C and CYP2D expression and activity during pregnancy in the rat: An OPRU study. 14th North American ISSX Meeting, Rio Grande, Puerto Rico (October)

Tasnif YO, Hebert MF, Calamia JC, Thummel KE. An in-vitro analysis of drug-

drug interactions between voriconazole and immunosuppressants (sirolimus, tacrolimus and cyclosporine). American College of Clinical Pharmacy Annual Meeting, St Louis MO (October)

2007 Audriani M, Buchanan ML, Pon V, Easterling T, Kaplan H, Carr D, Berg S,

Scorsone K, Ames M, Reid J, Petros W, McManus T, Reed E, Shen D, Swisher E, Skolnik J, Hebert MF. Pharmacokinetics of chemotherapy in pregnancy and lactation: An OPRU Network study. American College of Clinical Pharmacy Annual Meeting, Denver CO (October)

Buchanan ML, Easterling T, Carr D, Pon V, Shen D, Hebert MF. Clonidine in

Pregnancy: An OPRU Network study. American College of Clinical Pharmacy Annual Meeting, Denver CO (October)

Buchanan ML, Easterling T, Carr D, Hebert MF. Creatinine clearance during

pregnancy and postpartum: An OPRU Network study. American College of Clinical Pharmacy Annual Meeting, Denver CO (October)

Eyal S, Chung F, Muzi M, Hsiao P, Kaddoumi A, Link JM, Mankoff D, Hebert MF,

Unadkat JD. Effect of gestational-age on P-glycoprotein activity at the primate blood-brain (BBB) and the blood-placental barrier (BPB): An OPRU and UW SCOR study. 4th Annual North American ABC Genetic Workshop, Fredrick MD (October)

Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, Mao Q. Bcrp1 limits

fetal distribution of glyburide in pregnant mouse. An OPRU Network and UW SCOR study. AAPS Annual Meeting and Exposition, San Diego CA (November)

2008 Hebert MF, Naraharisetti SB, Ma X, Krudys KM, Umans J, Hankins GDV, Caritis

SN, Miodovnik M, Mattison DR, Unadak JD, Easterling TR, Vicini P. Are we guessing glyburide dosage in the treatment of gestational diabetes? The pharmacological evidence for better clinical practice. Society for Maternal Fetal Medicine Annual Meeting, Dallas TX (February)

Ma X, Vicini P, Krudys KM, Cobelli C, Umans J, Hankins GD, Caritis SN,

Miodovnik M, Mattison DR, Carr DR, Easterling TR, Hebert MF. Insulin sensitivity, beta-cell function and disposition index in gestational diabetes treated with glyburide monotherapy. American Diabetes Association 68th Scientific Sessions, San Francisco CA (June)

Andrew MA, Hebert MF, Vicini P for the OPRU Network. Physiologically based

pharmacokinetic model of midazolam disposition during pregnancy. IEEE EMBS Meeting, Vancouver BC Canada (August)


7/3/2018

2009 Rothberger S, Carr D, Buchanan M, Hebert M, Brateng D, Easterling T. Differential

pharmacodynamic responses to clonidine in pregnancy. SMFM 29th Annual Scientific Meeting, San Diego CA (January)

Kim JD, Eyal S, Anderson GD, Buchanan ML, Brateng D, Carr DB, Blough DK,

Woodrum DE, Easterling TE, Hebert MF. Atenolol pharmacokinetics and excretion in breast milk during the first 6-8 months postpartum. 2009 ACCP/ESCP International Congress on Clinical Pharmacy. Orlando FL (April)

Andrew MA, Hebert MF, Vicini P for the OPRU Network. Physiologically based

exploration of midazolam pharmacokinetics during pregnancy and postpartum. AAPS Biotechnology Conference. Seattle WA (June)

2010 Andrew MA, Hebert MF, Vicini P. Physiologically based pharmacokinetic

modeling of midazolam disposition in pregnant and postpartum women. 19th Population Approach Group Meeting. Berlin Germany (June) Zhan Y, Wang X, Rytting E, Patrikeeva S, Nanovskaya T, Clark S, Jackson A,

Venkataramanan R, Caritis S, Hebert M, Easterling T, Hankins G, Ahmed M. Pharmacokinetics of bupropion in pregnant women. Chicago IL (February)

2011 Yep T, Eyal S, Easterling TR, Shen DD, Kelly E, Hankins GDV, Caritis S, Risler L,

Hebert MF. The pharmacokinetics of metoprolol during pregnancy. American College of Clinical Pharmacy Annual Meeting, Pittsburgh PA (October)

2013 Lee N, Hebert MF, Easterling TR, Liang J, Rice K, Wang J. The organic cation

transporter 3 (OCT3) facilitates fetal disposition of metformin during pregnancy. ASPET, Boston MA (April)

Shuster D, Risler L, Liang J, Thummel K, Hebert M, Shen D, Mao Q. Gestational

age-dependent trends in maternal-fetal glyburide pharmacokinetics in pregnant mice. The American Conference on Pharmacometrics (ACoP), Fort Lauderdale FL (May).

2014 Quinney SK, Glassburn J, Hebert MF, Umans JG, Hankins GV, Caritis SN,

Flockhart DA, Haas DM. Omeprazole and esomeprazole pharmacokinetics in pregnancy. SMFM, New Orleans LA (February)

Feghali M, Hebert MF, Scifres C, Caritis SN. Relationship between glyburide and

insulin concentration in women with gestational diabetes. SMFM, New Orleans LA (February)

Cusumano M, Ryu R, Easterling TR, Shen D, Thummel K, Hebert MF. Hydralazine

Pharmacokinetics in Pregnancy. American College of Clinical Pharmacy Annual Meeting, Austin TX (October).

Ryu R, Bennett B, Easterling TR, Caritis S, Venkataramanan R, Umans J, Miodovnik

M, Ahmed M, Clark S, Thummel K, Shen DD, Hebert MF. Prednisone Pharmacokinetics in Pregnancy. American College of Clinical Pharmacy Annual Meeting, Austin TX (October).


7/3/2018

2015 Bennett B, Ryu R, Easterling TR, Caritis S, Venkataramanan R, Umans J, Miodovnik

M, Ahmed M, Clark S, Thummel K, Shen DD, Hebert MF. Prednisone pharmacokinetics during pregnancy and lactation. University of Washington 18th Annual Undergraduate Research Symposium, Seattle WA (May)

UNIVERSITY AND PUBLIC SERVICE University of Washington Service

1996-2007 Clinical Pharmacist, UWMC Liver Transplantation Clinic 1996-1999 Member, Thesis Committee 1997-1998 Chair, Therapeutics Faculty Search Committee (Hired Jeannine McCune) 1998-2000 Co-Chair, Therapeutics Graduate Program Committee 1998-2001 Member, Executive Committee 1998-2001 Member, School of Pharmacy Faculty Council 1999-2002 Member, School of Pharmacy Admissions Committee 2000-2002 Senator, UW Faculty Senate 2001-2005 Member, UW Faculty Senate Legislative Committee 2001 Mentor, University of Washington, Health Sciences Minority Student Program STAR (Stipend for Training Aspiring Researchers), Student: Nicole Gonzalez 2002-2003 Member Elmer Plein Endowed Research Award Committee 2003 Member, PORP Faculty Search Committee 2003-2004 Member, Liver Transplantation, Cholestatic Liver Injury Committee 2003-2004 Investigator, University of Washington Athletic Department 2004-2008 Member, K-12 Selection Committee 2005-2006 Chair, CE Planning Committee, Drugs in Pregnancy: Benchtop to Bedside 2006-2008 Member, CTSA planning committee 2007- Clinical Pharmacist, UWMC Obstetrics 2009-2014 Member, KL2 and TSP Selection Committee 2011-2013 School of Pharmacy PharmD Assessment Committee 2011-2013 School of Dentistry and Washington Dental Foundation, Drugs in Pregnancy

Guidelines for Dentists Development Committee 2012-2013 School of Pharmacy 4th year assessment sub-committee 2012-2018 Senator, UW Faculty Senate 2012-2014 Member, School of Pharmacy Senior Leadership Committee 2013 Member, UW Institute of Translational Health Sciences (ITHS), Strategic Planning

Committee 2013-2015 Member, UW Faculty Lecture Award Selection Committee 2013-2014 Chair, UW Department of Pharmacy Faculty Search Committee (Hired Brian

Werth) 2013-2014 Chair, School of Pharmacy Pharmacology Evaluation Committee 2013- Faculty Mentor, Terri O’Sullivan 2014-2015 Member, UW Department of Pharmacy Faculty Search Committee (PORPP

Director Position) 2014-2016 Chair, UW School of Pharmacy Senior Leadership Committee 2014-2015 Chair, UW School of Pharmacy Strategic Planning Committee 2015-2017 Member, KL2 Selection Committee 2016- Member, Senior Leadership Committee


7/3/2018

2016- Faculty Mentor, Cathy Yeung (informal) 2016-2019 Member, Senate Committee on Planning and Budgeting 2017 Member, Provost Committee on Faculty Effort Certification 2017- Co-Chair, Curriculum Innovation - Clinical and Population Therapeutics

Workgroup 2017- Member, Curriculum Innovation - Skills Experiential Education and Wednesdays

in Practice Workgroup 2017-2018 Leadership Project – Achieving Success for UW Student-Athletes in STEM Fields 2017 Member, Strategic Planning Committee, Department of Pharmacy 2017- Member, UW President’s Advisory Committee on Intercollegiate Athletics (ACIA) 2017-2018 Member, Provost’s Joint Taskforce on Supplement Distribution 2018 Member, Department of Pharmacy Promotion and Tenure Guidelines Committee 2018- Faculty Mentor, Melissa Barker-Haliski

UCSF Service

1993 –96 Member, Without Salary Faculty Peer Review Committee 1993-96 Member, Student Status Committee 1992 Member, P & T Subcommittee 1990-96 Member, Liver Transplant Patient Selection Committee 1992-96 Member, Transplant Teen Day Committee

Professional Service 1994-1996 Pharm Research reviewer

1998- ACCP Abstract reviewer 1999- The Annals of Pharmacotherapy reviewer 2000- Drug Metabolism and Disposition reviewer

2001-2002 Chair-Elect ACCP Transplant Focus Group

2001-2003 ACCP Research Award and Fellowship reviewer

2002-2003 Chair ACCP Transplant Focus Group

2002-2004 ACCP Program Planning Committee

2006-2007 ACCP Women’s Health PRN Program Planning Committee 2009-2011 ADA and ACOG Work Group to prevent cardiovascular disease in women with

a history of gestational diabetes mellitus 2009-2010 Seattle & King County Public Health Reserve Corps 2011 Health Resources and Services Administration, American College of Obstetrics

and Gynecology and the American Dental Association expert working group on perinatal oral health

2011 NIH Special Emphasis Panel Reviewer


7/3/2018

2012 Development of animal models of pregnancy to address medical

countermeasures in the "at risk" population of pregnant women: studies for influenza, FDA

Anthrax: Special Considerations for Pregnant and Postpartum Women Centers for Disease Control and Prevention 2014- Public Health Reserve Corps, Member 2014 NIH Special Emphasis Panel Reviewer 2014 Remote Area Medical Pharmacist Volunteer Seattle WA 2015 ACCP Global Conference Program Reviewer San Francisco CA 2017-2018 ACCP IMTR PRN Nominations Committee, Member 2018 NIH/NIGMS Reviewer

Community Service

1991 Soup Kitchen Volunteer, St. John of God 1993 -96 Project Open Hand Volunteer (delivered meals to home bound patients) 1996- Eucharistic Minister, St Matthew Parish 2002 St. Matthew RCIA Pharmacy Moral & Ethical Issues and the Catholic Church

(instructor) 2003 St. Matthew School Kindergarten Poison Control (instructor)

2004-05 St. Matthew School Parent’s Club Officer – Parent Education Coordinator 2004-07 St. Matthew Pastoral Council 2005-06 St. Matthew Pastoral Council Vice-President 2006 St. Matthew School Poison Control (instructor) 2006 St. Matthew Transition Team Chair 2006-07 St Mathew Pastoral Council President 2011 Teen Feed Volunteer, St Matthew Parish (prepare and serve meals to homeless

teens in Seattle) 2013- St Matthew Volunteer to Orphanage, Honduras 2016- Faculty mentor for students in UW sanctioned health fairs 2016 Operation Heart, Be Heart Smart, Overlake Hospital and Clinics (February) 2016 Operation Heart, Puget Sound Heart and Stroke Walk, Preceptor (October) 2017 OTC Literacy, Girl Scouts Outreach Event, Preceptor (January) 2017 Costco Health Fair, Preceptor (May) 2017 Pharmacists for Reproductive Education and Sexual Health, Preceptor (May) 2017 The Cliff Avril Family Foundation Health Fai, Preceptor (September) 2017- Member, St. Vincent de Paul (6 hours/week) 2017- Member, ACCP Immunology/Transplantation PRN Nominations Committee

RESEARCH AND CREATIVE ACTIVITY


7/3/2018

Summary of Current Research Interests

1. Pharmacokinetics/pharmacodynamics of immunosuppressive agents 2. Effect of liver disease on pharmacokinetics/pharmacodynamics 3. Intestinal Metabolism 4. Women’s Health / Drugs in Pregnancy and Lactation 5. Transplantation

Funded Research Awards, Fellowships and Extramural Grants Date Project Funding

Amount Funding Source

Role on Project

1991 Efficacy, safety and pharmacokinetics of tacrolimus in liver transplant patients

~$300,000 Fujisawa Co-Investigator

1991 Efficacy and safety of compassionate use of tacrolimus

~$200,000 Fujisawa Co-Investigator

1991 Efficacy and safety of compassionate use of mycophenolate mofetil

~$200,000 Syntex Co-Investigator

1991 Tacrolimus pharmacokinetics following liver transplantation

~$100,000 Fujisawa PI

1992-1996 Mechanisms of immunosuppressive drug interactions

~$1,500,000 NIH Co-Investigator

1993-1995 Pilot dose finding study of mycophenolate mofetil following liver transplantation

~$400,000 Syntex Co-Investigator

1993-1996 Cytogam prophylaxis following liver transplantation

$150,000 Medimmune Co-Investigator

1993-1995 Open-label dose-ranging, pharmacokinetic, safety and tolerance of PO and IV RS61443 in pediatric kidney and liver transplant recipients

Syntex Co-Investigator

1994 Effect of ketoconazole on cyclosporine pharmacokinetics

~$150,000 Sandoz Co-Investigator

1994 Steady state RS61443 pharmacokinetics in kidney and liver transplant patients

Syntex Co-Investigator

1995 Effect of ketoconazole on tacrolimus pharmacokinetics

$125,000 Fujisawa PI

1996 Evaluation of Pharmacist run vaccination clinics

$1549 Elmer M Plein Endowed Research Fund

PI

1996 Effect of rifampin on tacrolimus pharmacokinetics

$72,078 Fujisawa PI


7/3/2018

1997 Efficacy and safety of mycophenolate mofetil in liver transplantation

$270,000 Roche Co-PI

1997 High dose interferon for hepatitis C $240,000 Schering Co-Investigator 2000 Effect of St. John’s wort on tacrolimus

pharmacokinetics $3000 Elmer M.

Plein Endowed Research Fund

PI

9/30/01-3/29/04

Pharmacokinetics and pharmacodynamics of atenolol in pregnancy

$153,000 FDA PI

4/1/02-3/31/07 Genetic and hormonal regulation of CYP3A

$1,385,810 NIH Co-Investigator

10/02-9/06 Pharmacokinetics of amoxicillin during pregnancy and postpartum

$272,100 FDA PI

9/6/02-7/31/07 Mechanisms by which maternal and fetal drug exposure is altered during pregnancy


12/1/02-12/31/04

Micafungin pharmacokinetic analysis $75,800 Fujisawa PI

2003-2008 Pharmacokinetic/pharmacodynamic umbrella agreement

FDA PI

5/1/04-4/30/08 Pharmacogenetics of ADRs: calcineurin inhibitor toxicity


7/1/04-1/31/10 Obstetric-Fetal Pharmacology Unit $4,205,070 NIH/NICHD PI 9/1/04-9/30/08 Pharmacokinetics of atenolol during

lactation $220,000 FDA PI

9/17/07-5/31/12

Institute of Translational Health Sciences $47,775,116 NIH/NCRR Co-Investigator

9/15/09-1/31/10

ARRA Obstetric-fetal Pharmacology Research Unit

$868,197 NIH/NICHD PI

5/1/08-4/30/09 Pregnancy malaria $66,050 NIH/NIAID Subcontract to SBRI

PI

11/12/09-11/11/10

Pregnancy malaria $25,350 NIH/NIAID Subcontract to SBRI

PI

2/1/10-12/31/15

Obstetric-fetal Pharmacology Research Unit

$4,964,310 NIH/NICHD PI

7/15/17-3/31/21

Effect of retinoids on CYP2D6 activity and variability in special populations

$2,392,468

NIH/NIGMS PI

7/1/18-3/31/20 Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

$79,000 NIH/NICHD (Subcontract to Duke)

PI

Other Creative Endeavors

1990 UCSF Adult Liver Transplant Medication Manual 1992 UCSF Pediatric Liver Transplant Medication Manual


7/3/2018

1996 UW Liver Transplant Medication Manual

PUBLICATIONS Journal Articles

(1) Hebert MF. Ribavirin. Pharm. Ther. Forum 36, 1-4 (1988). (2) Hebert MF and Guglielmo BJ. What is the Clinical Role of Ribavirin? DICP Ann.

Pharmacother. 24, 735-738 (1990). (3) Hebert MF, Ascher NL, Lake JR, and Roberts JP. Efficacy and Toxicity of FK506 for the

Treatment of Resistant Rejection in Liver Transplant Patients. Transplant. Proc. 23, 3109-3110 (1991).

(4) Freise CE, Rowley H, Hebert MF, Ascher NL, and Roberts JP. Similar Clinical

Presentation of Neurotoxicity Following FK506 and CSA in Liver Transplant Recipient. Transplant. Proc. 23, 3173-3174 (1991).

(5) Hebert MF, Roberts JP, Preuksaritanont T, and Benet LZ. Bioavailability of Cyclosporine

with Concomitant Rifampin Administration is Markedly Less than Predicted by Hepatic Enzyme Induction. Clin. Pharmacol. Ther. 52, 453-457 (1992).

(6) Roberts JP, Lake JR, Hebert M, Nikolai B, Ascher NL, and Ferrell L. Reversal of Chronic

Rejection after Treatment Failure with FK506 and RS61443. Transplantation . 56, 1021-1023 (1993).

(7) Hebert MF and Roberts JP. End Stage Liver Disease Associated with Nitrofurantoin

Requiring Liver Transplantation. Ann. Pharmacother. 27,1193-1194 (1993).

(8) Freise CE, Hebert M, Osorio RW, Nikolai B, Lake JR, Kauffman RS, Ascher NL and Roberts JP. Maintenance Immunosuppression with Prednisone and RS-61443 Alone Following Liver Transplantation. Transplant. Proc. 25, 1758-9 (1993).

(9) Hebert MF and Roberts JP. Focus on tacrolimus: A new macrolide immunosuppressive

agent for liver transplant recipients. Hosp. Formul. 29, 447-453 (1994).

(10) The U.S. Multicenter FK 506 Liver Study Group. A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation. N. Engl. J. Med. 331, 1110-5 (1994).

(11) Jusko WJ, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P,

Mekki QA. Pharmacokinetics of Tacrolimus in Liver Transplant Patients. Clin. Pharmacol. Ther. 57, 281-290 (1995).


7/3/2018

(12) Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY and Wacher VJ. Differentiation of Absorption, First-Pass Gut and Hepatic Metabolism in Humans: Studies with Cyclosporine. Clin. Pharmacol. Ther. 58, 492-497 (1995).

(13) Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF and Benet LZ. The Effects of

Ketoconazole on the Intestinal Metabolism and Bioavailability of Cyclosporine. Clin. Pharmacol. Ther. 58, 15-19 (1995).

(14) Aboulijoud MS, Levy MF, Klintmalm GB, and the US Multicenter Study Group.

Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine US multicenter trial. Transplant. Proc. 27, 1121-1123 (1995).

(15) Benet LZ, Wu CY, Hebert MF and Wacher VJ. Intestinal Drug Metabolism and

Antitransport Processes: A Potential Paradigm Shift in Oral Drug Delivery. J Control Release 39, 139-43 (1996).

(16) Chang T, Benet LZ and Hebert MF. The Effect of Water-soluble Vitamin E on

Cyclosporine Pharmacokinetics in Healthy Volunteers. Clin. Pharmacol. Ther. 59, 297-303 (1996).

(17) Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF.

Tacrolimus Oral Bioavailability Doubles with Co-Administration of Ketoconazole. Clin. Pharmacol. Ther. 62, 41-49 (1997).

(18) Hebert MF. Contributions of Hepatic and Intestinal Metabolism and P-glycoprotein to

Cyclosporine and Tacrolimus Oral Drug Delivery. Adv. Drug Deliv. Rev. 27, 201-14 (1997).

(19) Floren LC, Hebert MF, Venook AP, Jordan VC, Cisneros A, Somberg KA. Tamoxifen in Liver Disease: Potential Exacerbation of Hepatic Dysfunction. Annal Onc 9, 1123-1126 (1998).

(20) Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of Rifampin on

Tacrolimus Pharmacokinetics in Healthy Volunteers. J. Clin. Pharmacol. 39, 91-96 (1999).

(21) Hebert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, Roberts JP. Four Year

Follow-up of Mycophenolate Mofetil for Graft Rescue in Liver Allograft Recipients. Transplantation 67, 707-712 (1999).

(22) A Report of the United States FK506 Study Group. A Long-Term Comparison of

Tacrolimus (FK506) versus Cyclosporine in Liver Transplantation. Transplantation. 66, 493-499 (1998).

(23) Hebert MF, Lam AY. Diltiazem Increases Tacrolimus Concentrations. Ann.

Pharmacother. 33, 680-682 (1999).

(24) Roche-Mycophenolate International Study Group. A randomized double blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteriods in primary liver transplant recipients. Liver Transplantation 2001;7:442-50.


7/3/2018

(25) Hebert MF and Hazlet TK. Cyclosporine is not just cyclosporine anymore. State Board of Pharmacy Newsletter April (2001).

(26) Hebert MF, Wacher VJ, Roberts JP, Benet LZ. Pharmacokinetics of cyclosporine pre- and

post-liver transplantation. J Clin Pharmacol 43:38-42 (2003).

(27) Park JM, Lin YS, Calamia JC, Thummel KE, Slattery JT, Kalhorn TF, Carithers RL, Levy AE, Marsh CL, Hebert MF. Transiently altered acetaminophen metabolism after liver transplantation. Clin Pharmacol Ther 73:545-553 (2003).

(28) Hebert MF, Dowling ALS, Gierwatowski C, Lin YS, Edwards KL, Davis CL, Marsh CL,

Schuetz EG, Thummel KI. Association between MDR1 (multidrug resistance transporter) genotype and post liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 13:1-14 (2003).

(29) Hebert MF. Drug Interactions of Antifungal Agents in Transplant patient. US Pharmacist

28:HS34-HS42 (2003).

(30) Hebert MF, Park JM, Chen Y-L, Akhtar S, Larson AM. Effects of St. John’s wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 44:89-94 (2004).

(31) Hebert MF, Carr DB, Anderson GD, Blough D, Green GE, Brateng DA, Kantor E,

Benedetti TJ, Easterling TR. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol 45:25-33 (2005).

(32) Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, Thummel KE.

In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68:1889-1902 (2004).

(33) Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D, Keirns J, Bekersky I.

Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45:954-60 (2005).

(34) Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, Bekersky I.

Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45:1018-24 (2005).

(35) Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns

J, Bekersky I. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease and volunteers with renal dysfunction. J Clin Pharmacol 45:1145-52 (2005).

(36) Gupta A, Dai Y, Vethanayagam RR, Hebert M, Thummel K, Unadkat J, Ross D, Mao Q.

Cyclosporine A, tacrolimus and sirolimus are potent inhibitors of human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374-83 (2006).

(37) Dai Y, Hebert MF, Isoherranen N, Davis CL, Perkins JK, Marsh C, Shen D, Thummel KE.

Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836-47 (2006).


7/3/2018

(38) Andrew MA, Easterling TR, Carr DB, Shen D, Blough D, Buchanan ML, Rutherford T, Bennett R, Duchin JS, Vicini P, Hebert MF. Amoxicillin pharmacokinetics, modeling and simulations during pregnancy and postpartum. Clin Pharmacol Ther 81:547-56. (2007).

(39) Hebert MF, Easterling TR, Kirby B, Carr DB, Buchanan ML, Rutherford T, Thummel KE,

Fishbein DP, Unadkat JD. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a UW SCOR study. Clin Pharmacol Ther 84:248-53 (2008).

(40) Naraharisetti SB, Kirby BJ, Hebert MF, Easterling TR, Unadkat JD. Validation of a

sensitive LC-MS assay for quantification of glyburide and its metabolite 4-hydroxy glyburide in plasma and urine: An OPRU Network study. J Chromotogr B 860:34-41 (2007).

(41) Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, Mao Q. The breast cancer

resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse – An OPRU Network and UW SCOR study. Mol Pharmacol 73:949-59 (2008).

(42) Dickmann LJ, Tay S, Senn TD, Zhang H, Visone A, Unadkat JD, Hebert MF, and

Isoherranen N. Changes in Maternal liver Cyp2c and Cyp2d Expression and Activity During Rat Pregnancy. Biochem Pharmacol 75:1677-87 (2008).

(43) Mikheev AM, Nabekura T, Kaddoumi A, Bammler TK, Govindarajan R, Hebert MF,

Unadkat JD. Profiling gene expression in human placentae of different gestational ages: an OPRU Network and UW SCOR study. Reproductive Sciences 15:866-77 (2008).

(44) Kirby BJ, Kalhorn T, Hebert M, Easterling T, Unadkat JD. Sensitive and specific LC-MS

assay for quantification of digoxin in human plasma and urine. Biomed Chromatogr 22:712-18 (2008).

(45) Smith HE, Jones JP, Kalhorn TF, Farin FM, Stapleton PL, Davis CL, Perkins JD, Blough DK, Hebert MF, Thummel KE, Totah RA. Role of cytochrome P450 2C8 and 2J2 genotype in calcineurin inhibitor induced chronic kidney disease. Pharmacogenet Genomics 18:943-53 (2008).

(46) Buchanan ML, Easterling TR, Carr DB, Shen DD, Risler LJ, Nelson WL, Mattison DR,

Hebert MF. Clonidine Pharmacokinetics in Pregnancy. Drug Metab Dispos. 2009;37:702-5.

(47) Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GDV, Caritis SN,

Miodovnik M, Mattison DR, Unadkat JD, Kelly EJ, Blough D, Cobelli C, Ahmed MS, Snodgrass WR, Carr DB, Easterling TR, Vicini P for the Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 85;607-14 (2009).

(48) Eyal S, Chung FS, Muzi M, Link JM, Mankoff DA, Kaddoumi A, O’Sullivan F, Hebert

MF, Unadkat JD. Simultaneous PET Imaging of P-Glycoprotein Inhibition in Multiple Tissues in the Pregnant Non-Human Primate. J Nuclear Med 50:798-806 (2009).

(49) Andrew MA, Hebert MF, Vicini P, "Physiologically based pharmacokinetic model of

midazolam disposition during pregnancy," Engineering in Medicine and Biology Society,


7/3/2018

2008. EMBS 2008. 30th Annual International Conference of the IEEE. 20-25 Aug. 2008:5454-7.

(50) Haas DM, Hebert MF, Soldin OP, Flockhart DA, Madadi Parvaz, Noncon JJ, Chambers

CD, Hankins GD, Clark S, Wisner KL, Li L, Renbarger JL, Learman LA. Pharmacotherapy and Pregnancy: Highlights for the Second International Conference for Individualized Pharmacotherapy in Pregnancy. Clin Transl Sci 2:439-43 (2009).

(51) Eyal S, Kim JD, Anderson GD, Buchanan ML, Brateng DA, Carr D, Woodrum DE,

Easterling TR, Hebert MF. Atenolol Pharmacokinetics and Excretion in Breast Milk during the first 6-8 Months Postpartum. J Clin Pharmacol 50:1301-9 (2010).

(52) Zhou L, Naraharisetti SB, Liu L, Wang H, Lin YS, Isoherranen N, Unadkat JD, Hebert

MF, Mao Q. Contributions of Human Cytochrome P450 Enzymes to Glyburide Metabolism. Biopharm Drug Dispos 31:228-42 (2010).

(53) Eyal S, Easterling TR, Carr D, Umans JG, Miodovnik M, Hankins GDV, Clark SM, Risler

L, Wang J, Kelly EJ, Shen DD, Hebert MF. Pharmacokinetics of Metformin during pregnancy. Drug Metab Dispos 38:833-40 (2010).

(54) Zhou L, Zhang Y, Hebert MF, Unadkat JD, Mao Q. Increased Glyburide Clearance in the

Pregnant Mouse Model. Drug Metab Dispos 38:1403-6 (2010). (55) Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF. CYP2D6 Mediates 4-

Hydroxylation of Clonidine In Vitro: Implication for Pregnancy-Induced Changes in Clonidine Clearance. Drug Metab Dispos 38:1393-6 (2010).

(56) Rothberger S, Carr D, Brateng D, Hebert M, Easterling T. Pharmacodynamics of

Clonidine Therapy in Pregnancy: a Heterogeneous Maternal Response Impacts Fetal Growth. Am J HTN 23:1234-40 (2010).

(57) Beigi RH, Han K, Venkataramanan R, Hankins GD, Clark S, Hebert MF, Easterling T,

Zajicek A, Ren Z, Mattison DR, Caritis SN. Pharmacokinetics of Oseltamivir among pregnant and non-pregnant women. Am J Obstet Gynecol 204:S84-8 (2011).

(58) Haas DM, Gallauresi B, Shields K, Zeitlin D, Clark SM, Hebert MF, Ren Z, Nallani SC,

Meslin EM, Feibus KB, Koren G, Goebel WS, Easterling T, Denne SC, Flockhart DA, Renbarger JL. Pharmacotherapy and pregnancy: highlights from the third international conference for individualized pharmacotherapy in pregnancy. Clin Trans Sci 2011;4:204-9 (2011).

(59) Wang Z, Senn T, Kalhorn T, Zheng XE, Zheng S, Davis CL, Hebert MF, Lin YS, Thummel

KE. Simultaneous measurement of plasma vitamin D(3) metabolites, including 4β,25-dihydroxyvitamin D(3), using liquid chromatography-tandem mass spectrometry. Anal Biochem. 418:126-33 (2011).

(60) Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD,

Baillie TA, Hebert MF, Blough D, Davis CL, Thummel KE. Inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway represents a possible mechanism for drug-induced osteomalacia. Molecular Pharmacol 81:498-509 (2012).


7/3/2018

(61) Quinney SK, Mahamed AN, Hebert MF, Haas DM, Clark S, Umans JG, Caritis SN, Li L. A semi-mechanistic metabolism model of CYP3A substrates in pregnancy: predicting changes in midazolam and nifedipine pharmacokinetics. CPT: Pharmacometrics & Systems Pharmacology (2012) Sep 26;1:e2.

(62) van Hasselt JGC, Andrew MA, Hebert MF, Tarning J, Vicini P, Mattison DR. The Status

of Pharmacometrics in Pregnancy: Highlights from the 3rd American Conference on Pharmacometrics. Br J Clin Pharmacol 74:932-939 (2012).

(63) Caritis SN, Sharma S, Venkataramanan R, Hankins G, Miodovnik M, Hebert MF, Umans

JG, Benedetti T, Mattison D, Zajicek A, Fischer D, Jackson A. Pharmacology and Placental Transport of 17-Hydroxyprogesterone Caproate in Singleton Gestation. Am J Obstet Gynecol (2012) 207:398.e1-8.

(64) Haas DM, Quinney SK, Clay J, Renbarger JL, Hebert MF, Clark S, Umans J, Caritis SN,

for the Obstetric-fetal Pharmacology Research Units Network. Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Am J Perinatol (2013) 30:275-82.

(65) Zheng S, Easterling TR, Umans JG, Miodovnik M, Calamia JC, Thummel KE, Shen DD,

Davis CL, Hebert MF. Pharmacokinetics of Tacrolimus During Pregnancy. Ther Drug Monit 34:660-70 (2012).

(66) Hebert MF, Zheng S, Hays K, Shen DD, Davis CL5, Umans JG6, Miodovnik M, Thummel

KE3, Easterling TR. Interpreting Tacrolimus Concentrations During Pregnancy and Postpartum. Transplantation (2013) 95:908-915.

(67) Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin Y, Shen DD,

Thummel KE. CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. Transplantation (2012) 95:821-7.

(65) Shuster DL, Bammler TK, Beyer RP, MacDonald JW, Tsai JM, Farin FM, Hebert MF,

Thummel KE, Mao Q. Gestational age-dependent changes in gene expression of metabolic enzymes and transporters in pregnant mice. Drug Metab Dispos (2012) 41:332-42.

(66) Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD,

Thummel KE. Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther (2012) 92(6)737-45.

(67) Caritis SN, Hebert MF. A pharmacological approach to the use of glyburide in

pregnancy. Obstet Gynecology (2013) Jun;121(6):1309-12. (68) Hays K, Ryu RJ, Swisher EM, Reed E, McManus T, Rybeck B, Petros WP, Hebert MF.

Duration of cisplatin excretion in breast milk. J Human Lac (2013) Nov;29(4):469-72. (69) Zheng S, Easterling TR, Hays K, Umans JG, Miodovnik M, Clark S, Calamia JC, Thummel

KE, Shen DD, Davis CL, Hebert MF. Tacrolimus placental transfer at delivery and neonatal exposure through breast milk. Br J Clin Pharmacol (2013) 76:988-96.


7/3/2018

(70) Lee N, Hebert MF, Prasad B, Easterling TR, Kelly EJ, Unadkat JD, Wang J. Effect of gestational age on mRNA and protein expression of polyspecific organic cation transporters during pregnancy. Drug Metab Dispos (2013) Dec;41(12):2225-32.

(71) Hebert MF. Impact of pregnancy on pharmacokinetics of medications. J Pop Ther Clin

Pharmacol (2013) 20:e350-7. (72) Ryu RJ, Eyal S, Kaplan HG, Akbarzadeh A, Hays K, Puhl K, Easterling TR, Berg SL,

Scorsone KA, Feldman EM, Umans JG, Miodovnik M, Hebert MF. Pharmacokinetics of doxorubicin in pregnant women. Cancer Chemother Pharmacol (2014) 73:789-97.

(73) Ryu RJ, Hays KE, Hebert MF. Gestational diabetes mellitus management with oral

hypoglycemic agents. Seminars Perinatol (2014) 38:508-15. (74) Shuster DL, Risler LJ, Liang C-K J, Rice KM, Shen DD, Hebert MF, Thummel KE, Mao Q.

Maternal-fetal disposition of glyburide in pregnant mice is dependent on gestational age. J Pharmacol Exper Ther (2014) 350:425-34.

(75) Zhao Y, Hebert M, Venkataramanan. Basic Obstetric Pharmacology. Seminars Perinatol

(2014) 38:475-86. (76) Lee N, Duan H, Hebert MF, Liang CJ, Rice KM, Wang J. Taste of a pill: organic cation

transporter 3 mediates drug accumulation and secretion in salivary glands. J Bio Chem (2014) 289:27055-64.

(77) Shuster DL, Risler LJ, Prasad B, Calamia JC, Voellinger JL, Kelly EJ, Unadkat JD, Hebert

MF, Shen DD, Thummel KE. Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol (2014) 92:690-700.

(78) Pillai VC, Han K, Beigi RH, Hankins GD, Clark S, Hebert MF, Easterling TR, Zajicek A,

Ren Z, Caritis SN, Venkataramanan R. Population Pharmacokinetics of Oseltamivir in Non-Pregnant and Pregnant Women. Br J Clin Pharmacol. 2015 Nov;80(5):1042-50.

(79) Ryu RJ, Eyal S, Easterling TR, Caritis SN, Venkataraman R, Hankins G, Rytting E,

Thummel K, Kelly EJ, Risler L, Phillips B, Honker MT, Shen DD and Hebert MF. Pharmacokinetics of Metoprolol during Pregnancy and Lactation. J Clin Pharmacol (2016) 56:581-9. NIHMSID 894049

(80) Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, Easterling TR,

Haas DM, Haneline LS, Caritis SN, Venkataramanan R, West H, D’Alton M, Hankins G for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network (OPRU). Safety and pharmacokinetics of pravastatin used for the prevention of preelampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol (2015) 214(6):720.e1-720.e17.

(81) Dorfman E, Thummel K, Cheng E, Hebert MF and Burke W. Prenatal

Pharmacogenomics: A promising area for research. Pharmacogenomics J. (2016) 16(4):303-4.

(82) Tasnif Y, Morado J, and Hebert MF. Pregnancy-Related Pharmacokinetic Changes. Clin

Pharmacol Ther (2016) 100:53-62.


7/3/2018

(83) Sharma S, Caritis S, Fischer D, Hankins G, Miodovnik M, Hebert MF, Mattison D, Zajicek

A and Venkatramanan R. Population Pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation. Br J Clin Pharmacol (2016) 82(4):1084-93.

(84) Lemon LS, Zhang H, Hebert MF, Hankins GD, Hass DM, Caritis SN, Venkataramanan R.

Patient exposure to ondansetron changes during pregnancy. Pharmacotherapy (2016) 36(9):e139-41.

(85) Bergagnini-Kolev MC, Hebert MF, Easterling TR, Lin YS. Pregnancy Increases the Renal

Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. Drug Metab Dispos. 2017 Mar;45(3):325-329.

(86) Caritis SN, Hankins G, Hebert M, Haas DM, Ahmed M, Simhan H, Haneline LA, Harris

J, Chang J, Stephenson Famy A, Yorio P, Ren Z, D’Alton ME, Venkataramanan R. Impact of Pregnancy History and 17-hydroxyprogesterone caproate (17-OHPC) on Cervical Cytokines and Matrix Metalloproteinases. Am J Perinatol. (2017) 2018 Apr;35(5):470-480.

(87) Zha W, Ho HTB, Hu T, Hebert MF, Wang J. Serotonin transporter deficiency drives estrogen-dependent obesity and glucose intolerance. Sci Rep. 2017 Apr 25;7(1):1137.

(88) Kantrowitz-Gordon I, Hays K, Kayode O,Kumar AR, Kaplan HG, Reid JM, Safgren SL, Ames MM, Easterling TR and Hebert MF. Pharmacokinetics of Dacarbazine (DTIC) in Pregnancy. Cancer Chemother Pharmacol (2018) Mar; 81(3), 455-460.

(89) Palmsten K, Rolland M, Hebert MF, Clowse MEB, Schatz M, Xu R, Chambers CD. Patterns of prednisone use during pregnancy: daily and cumulative dose. Pharmacoepidemiol Drug Saf. 2018 Apr;27(4):430-438.

(90) Ryu RJ, Easterling TR, Caritis SN, Venkataramanan R, Umans JG, Ahmed MS, Clark S,

Kantrowitz-Gordon I, Hays K, Bennett B, Honaker MT, Thummel KE, Shen DD, Hebert MF. Prednisone Pharmacokinetics During Pregnancy and Lactation. J Clin Pharmacol. 2018 May 7. doi: 10.1002/jcph.1122. [Epub ahead of print]

(91) Easterling TR, Hebert MF, Bracken H, Darwish E, Ramadan MC, Shaarawy S, Charles D,

Abdel-Aziz T, MD; Nasr AS, Safwal SM, Winikoff B. A randomized trial comparing the pharmacology of magnesium sulfate when used to treat severe preeclampsia with serial intravenous boluses versus a continuous intravenous infusion. BMC Pregnancy and Childbirth. 2018 (Accepted for publication).

Book Chapters

(1) Hebert MF. Gastroesophogeal reflux and peptic ulcer disease cases. In Hart LL, Gourley DR, and Herfindal ET, eds. A Workbook to Accompany Clinical Pharmacy and Therapeutics. Baltimore: Williams and Wilkins; 1988.

https://www.ncbi.nlm.nih.gov/pubmed/28442777




7/3/2018

(2) Hebert MF. Gastroesophogeal reflux and peptic ulcer disease cases. In Hart LL, Gourley DR, and Herfindal ET, eds. A Workbook to Accompany Clinical Pharmacy and Therapeutics. Baltimore: Williams and Wilkins; 1992.

(3) Hebert MF. Gastroesophogeal reflux and peptic ulcer disease cases. In Hart LL, Gourley

DR, and Herfindal ET, eds. A Workbook to Accompany Clinical Pharmacy and Therapeutics. Baltimore: Williams and Wilkins; 1996.

(4) Hebert MF. Guide to drug dosage in hepatic disease. In Speight TM ed. Avery's Drug

Treatment 4th Edition. Auckland, Sydney: ADIS Press Limited; 1997:1761-1792 (5) Hebert MF. Immunosuppressive Agents . In Levy RH, Thummel KE, Trager WF,

Hansten PD and Eichelbaum M eds. Metabolic Drug Interactions. Philadelphia: Lippencott - Raven Publishers; 2000:499-510.

(6) Hebert MF, Davis CL, Limaye AP, Kowdley KV, Carithers RL. Liver Transplantation:

Long-Term Post-Transplant Management . In Bacon & Di Bisceglie eds. Liver Disease: Diagnosis & Management. Philadelphia: W.B. Saunders Co.; 2000: 392-404.

(7) Hebert MF. Hepatitis: Viral and Drug Induced. In Herfindal and Gourley eds. Clinical

Pharmacy and Therapeutics Seventh Edition. Baltimore: Williams and Wilkins; 2000: 589-601.

(8) Hebert MF, Taylor SL and Carithers RL. Immunomodulating agents and the transplant

situation. In Kaplowitz and DeLeve eds. Drug-Induced Liver Disease. Second Edition. New York: Marcel Dekker, Inc.; 2003: 633-651.

(9) Hebert MF. Drug Interactions in Transplantation. In Building a Treatment Strategy for

Long-term Transplant Patient Care, Continuing Education. Chicago: CPE Communications 2003: 25-40.

(10) Hebert MF. Hepatitis: Viral and Drug Induced. In Helms R, Quan DJ, Herindal ET,

Gourley DR eds. Textbook of Therapeutics. Drug and Disease Management. Eighth Edition. Baltimore: Williams and Wilkins; 2006: 1331-45.

(11) Tasnif Y, Hebert MF. Complications of End Stage Liver Disease. In Koda-Kimble MA,

Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK, Corelli RL eds. Applied Therapeutics. The Clinical Use of Drugs Ninth Edition. Baltimore: Lippincott Williams & Wilkins; 2008.

(12) Tasnif Y, Hebert MF. Complications of End Stage Liver Disease. In Koda-Kimble MA,

Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK, Corelli RL eds. Applied Therapeutics. The Clinical Use of Drugs Tenth Edition. Baltimore: Lippincott Williams & Wilkins; 2012.

(13) Shuster DL, Hebert MF, Mao Q. Glyburide Disposition During Pregnancy. In

Radenkovic M ed. Gestational Diabetes. Rijeka, Croatia: InTech Open Access Publisher; 2011.

(14) Hebert MF. Impact of Pregnancy on Maternal Pharmacokinetics of Medications, chapter

in Clinical Pharmacology During Pregnancy, San Diego: Elsevier; 2013.


7/3/2018

(15) Kim J, Hebert MF. Medications Use in Pregnancy and Lactation with Musculoskeletal Conditions. In Musculoskeletal Health in Pregnancy and Postpartum: A Guide for Clinicians. Fitzgerald C and Segal N eds. New York: Springer; 2015.

(16) Tasnif Y, Hebert MF. Complications of End Stage Liver Disease. Applied Therapeutics.

The Clinical Use of Drugs Eleventh Edition. Baltimore: Lippincott Williams & Wilkins; 2018.

university of washingtonmont treblant, quebec, canada (july) effects of pregnancy on cyp3a and...

Documents